ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 360 filers reported holding ROYALTY PHARMA PLC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $829 | -13.2% | 31,471 | 0.0% | 0.02% | -12.5% |
| Q1 2024 | $955 | +8.0% | 31,471 | 0.0% | 0.02% | -4.0% |
| Q4 2023 | $884 | -6.6% | 31,471 | -9.8% | 0.02% | -7.4% |
| Q3 2023 | $946 | -18.7% | 34,886 | -7.8% | 0.03% | -6.9% |
| Q2 2023 | $1,163 | -30.5% | 37,835 | -18.6% | 0.03% | -17.1% |
| Q1 2023 | $1,674 | -27.2% | 46,470 | -20.2% | 0.04% | -12.5% |
| Q4 2022 | $2,301 | -99.9% | 58,230 | +1.1% | 0.04% | -9.1% |
| Q3 2022 | $2,313,000 | -4.5% | 57,580 | 0.0% | 0.04% | +2.3% |
| Q2 2022 | $2,423,000 | +8.0% | 57,580 | 0.0% | 0.04% | +26.5% |
| Q1 2022 | $2,243,000 | -1.7% | 57,580 | +0.5% | 0.03% | +6.2% |
| Q4 2021 | $2,282,000 | +68.9% | 57,280 | +53.2% | 0.03% | +88.2% |
| Q3 2021 | $1,351,000 | -11.8% | 37,387 | 0.0% | 0.02% | -10.5% |
| Q2 2021 | $1,532,000 | -6.0% | 37,387 | 0.0% | 0.02% | -13.6% |
| Q1 2021 | $1,630,000 | +315.8% | 37,387 | +376.8% | 0.02% | +340.0% |
| Q4 2020 | $392,000 | – | 7,842 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |